Pancreas-derived mesenchymal stromal cells share immune response-modulating and angiogenic potential with bone marrow mesenchymal stromal cells and can be grown to therapeutic scale under Good Manufacturing Practice conditions

Thirlwell, K. L., Colligan, D., Mountford, J. C., Samuel, K., Bailey, L., Cuesta-Gomez, N., Hewit, K. D., Kelly, C. J., West, C. C., McGowan, N. W., Casey, J. J., Graham, G. J., Turner, M. L., Forbes, S. and Campbell, J. D.  Pancreas-derived mesenchymal stromal cells share immune response-modulating and angiogenic potential with bone marrow mesenchymal…

Read More

Rationale and design of a randomized controlled trial of allogeneic mesenchymal stem cells in patients with nonischemic cardiomyopathy.

Greene SJ, Epstein SE, Kim RJ, Quyyumi AA, Cole RT, Anderson AS, Wilcox JE, Skopicki HA, Sikora S, Verkh L, Tankovich NI, Gheorghiade M, Butler J. Rationale and design of a randomized controlled trial of allogeneic mesenchymal stem cells in patients with nonischemic cardiomyopathy. Journal of Cardiovascular Medicine, published ahead of print. doi: 10.2459/JCM.0000000000000303

Read More